VEGFA and pulmonary arterial hypertension: As RHF is a leading cause of mortality in PAH patients, many experimental studies have used rodent models of PAH, induced either by injection of the vascular endothelial growth factor (VEGF) inhibitor, Sugen 5416, followed by hypoxia (SuHx) or the injection of monocrotaline (MCT), a pneumotoxic pyrrolizidine alkaloid.